发明授权
US08252796B2 1-butyl-2-hydroxyaralkyl piperazine derivatives and the uses as anti-depression medicine thereof
有权
1-丁基-2-羟基烷基哌嗪衍生物及其作为抗抑郁药的用途
- 专利标题: 1-butyl-2-hydroxyaralkyl piperazine derivatives and the uses as anti-depression medicine thereof
- 专利标题(中): 1-丁基-2-羟基烷基哌嗪衍生物及其作为抗抑郁药的用途
-
申请号: US13122691申请日: 2009-09-29
-
公开(公告)号: US08252796B2公开(公告)日: 2012-08-28
- 发明人: Jianqi Li , Na Lv , Hua Jin , Zhijie Weng , Yongyong Zheng
- 申请人: Jianqi Li , Na Lv , Hua Jin , Zhijie Weng , Yongyong Zheng
- 申请人地址: CN CN
- 专利权人: CSPC Zhonggi Pharmaceutical Technology (Shijiazhuang) Co. Ltd.,Shanghai Institute of Pharmaceutical Industry
- 当前专利权人: CSPC Zhonggi Pharmaceutical Technology (Shijiazhuang) Co. Ltd.,Shanghai Institute of Pharmaceutical Industry
- 当前专利权人地址: CN CN
- 代理机构: Schwegman, Lundberg & Woessner, P.A.
- 优先权: CN200810043821 20081007
- 国际申请: PCT/CN2009/074314 WO 20090929
- 国际公布: WO2010/040315 WO 20100415
- 主分类号: A61K31/495
- IPC分类号: A61K31/495 ; C07D241/04
摘要:
The invention discloses 1-butyl-2-hydroxyl aralkyl piperazine derivatives and their use as antidepressants. The derivatives of the present invention have triple inhibition effect on the reuptake of 5-HT, NA and DA, and can be administrated to the patients in need thereof in form of composition by route of oral administration, injection and the like. Compared with clinically currently used dual targets antidepressants (such as venlafaxine), said derivatives may have stronger antidepression effect, broader indications, faster onset and lower neurotoxicity and side reaction; and said derivatives have stronger antidepression activity, lower toxicity, higher bioavailability, longer half life and better druggablity, compared with aryl alkanol piperazine derivatives and optical isomers thereof disclosed in prior art. The 1-butyl-2-hydroxyl aralkyl piperazine derivative is the free alkali or its salt of a compound of formula below:
公开/授权文献
信息查询